5836 Federal Register / Vol. 62, No. 26 / Friday, February 7, 1997 / Notices

Access Research Careers [MARC]; and

93.375, Minority Biomedical Research

Support [MBRS])

Dated: January 31, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97–3078 Filed 2–6–97; 8:45 am]

BILLING CODE 4140–01–M

Office of Extramural Research; Notice

of Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the Peer

Review Oversight Group (PROG) on

February 13–14, 1997, in the Rockledge

II Centre, 6701 Rockledge Drive,

Bethesda, Maryland 20817. The meeting

will be held from 8:30 a.m. to 5 p.m. on

February 13 and from 8:30 a.m. to 12

p.m. on February 14. The meeting is

open to the public, with attendance

limited to space available.

Topics for discussion include: NIH

extramural electronic reinvention

activities, the rating of grant

applications, the integration of

Neuroscience Reviews, and the review

of multiple mechanisms within one

review group.

The meeting agenda and roster of

committee members are available on the

World Wide Web via the NIH Home

Page (http://www.nih.gov.grants/) or

from Dr. Peggy McCardle, Executive

Secretary, PROG, and Special Assistant

to the Deputy Director for Extramural

Research, OD, NIH, Building 1, Room

150, Bethesda, Maryland 20892, (301)

402–2246. Individuals who plan to

attend the meeting and need special

assistance, such as sign language

interpretation or other special

accommodations, should contact Dr.

McCardle by February 7, 1997.

This meeting is being published less

than 15 days prior to the meeting due

to the urgent need to proceed with the

meeting as scheduled in order to

address these issues in a timely manner.

Dated: January 31, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97–3079 Filed 2–6–97; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive

License: Particle-Medicated Gene

Delivery DNA Vaccines Against

Dengue and Other Flavivirus Infections

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 15 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of a limited field of use

exclusive world-wide license to practice

the invention embodied in U.S. Patent

No. 5,494,671, issued February 27, 1996

(U.S. Patent Application Serial No. 07/

747,785, filed August 20, 1991), entitled

‘‘C-Terminally Truncated Dengue and

Japanese Encephalitis Virus Envelope

Proteins’’; U.S. Patent Application

Serial No. 08/250,802, filed May 27,

1994, entitled ‘‘Chimeric and/or Growth

Restricted Flaviviruses’’ and related

foreign patent applications to Auragen,

Inc./Geniva, Inc. of Middleton, WI. The

patent rights in these inventions have

been assigned to the United States of

America.

SUPPLEMENTARY INFORMATION: The

prospective exclusive license will be

royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. It is anticipated

that this license may be limited to

particle-mediated gene delivery DNA

vaccines against Dengue and other

flavivirus infections. This license will

not include live virus, killed virus, or

protein-based vaccines. This

prospective exclusive license may be

granted unless within 60 days from the

date of this published notice, NIH

receives written evidence and argument

that establishes that the grant of the

license would not be consistent with the

requirements of 35 U.S.C. 209 and 37

CFR 404.7.

The patent describes the use of Cterminally truncated flavivirus envelope

proteins in vaccines against flavivirus

infections and also relates to

recombinant viruses which encode the

truncated protein. The patent

applications are directed to

recombinant, modified or viable

chimeric flaviviruses for use in vaccine

preparations against flavivirus

infections. This technology further

provides for a baculovirus having a

recombinant dengue cDNA sequence

which encodes dengue proteins and for

a baculovirus having a recombinant

Japanese B encephalitis virus cDNA

sequence which encodes Japanese B

encephalitis proteins. The applications

also relate to vaccines produced from

recombinant DNA.

ADDRESSES: Requests for a copy of the

issued patent, patent application,

inquiries, comments, and other

materials relating to the contemplated

license should be directed to: Gloria H.

Richmond, Patent Advisor, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, MD 20852–3804;

Telephone: (301) 496–7057 ext 268;

Facsimile: (301) 402–0220; E-mail:

Gloria Richmond@NIH.GOV. A signed

Confidential Disclosure Agreement will

be required to receive a copy of the

patent application. Applications for a

non-exclusive or exclusive license filed

in response to this notice will be treated

as objections to the grant of the

contemplated license. Only written

comments and/or applications for a

license which are received by NIH on or

before April 8, 1997 will be considered.

Comments and objections submitted in

response to this notice will not be made

available for public inspection, and, to

the extent permitted by law, will not be

released under the Freedom of

Information Act, 5 U.S.C. 552.

Dated: January 28, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–3080 Filed 2–6–97; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive

License: Vaccines for Dengue and

Other Flaviviruses

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 15 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of a limited field of use

exclusive world-wide license to practice

the invention embodied in U.S. Patent

No. 5,494,671, issued February 27, 1996

(U.S. Patent Application Serial No. 07/

747,785, filed August 20, 1991), entitled

‘‘C-Terminally Truncated Dengue and

Japanese Encephalitis Virus Envelope

Proteins’’ to Hawaii Biotechnology

Group, Inc. of Aiea, Hawaii. The patent

rights in this invention have been

assigned to the United States of

America.

SUPPLEMENTARY INFORMATION: The

prospective exclusive license will be

royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. It is anticipated

that this license may be limited to the

field of subunit vaccines against Dengue

and Japanese Encephalitis produced in

animal cells. This license will not

include live virus, killed virus or DNAbased vaccines or the use of vaccinia

virus as a vector, or immunogen. This

prospective exclusive license may be

granted unless within 60 days from the